Formycon AG (FYB.F)

41.65 -2.65 (-5.98%) At close: 09:50PM CEST

Formycon AG

Fraunhoferstrasse 15
Martinsried
Planegg 82152
Germany
49 89 864 667 100
https://www.formycon.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 238

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stefan Glombitza	CEO & Member of Executive Board	N/A	N/A	1965
Dr. Friedrich-Wilhelm Steinweg	Co-Founder	N/A	N/A	N/A
Dr. Nicolas Combe Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Enno Spillner	CFO & Member of Management Board	N/A	N/A	1970
Dr. Andreas Seidl	Chief Scientific Officer & Member of Executive Board	N/A	N/A	1971
Ms. Nicola Mikulcik	Chief Business Officer & Member of Executive Board	N/A	N/A	1972
Sabrina Muller	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Corporate governance

Formycon AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.